Cited by 833CAR-T cell therapy researchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Open access

Rafiq, Sarwish, Yeku, Oladapo O, Jackson, Hollie J, Purdon, Terence J, van Leeuwen, Dayenne G, Drakes, Dylan J, Song, Mei, Miele, Matthew M, Li, Zhuoning, Wang, Pei, Yan, Su, Xiang, Jingyi, Ma, Xiaojing, Seshan, Venkatraman E, Hendrickson, Ronald C, Liu, Cheng, Brentjens, Renier J·2018·Nature Biotechnology

DOI 10.1038/nbt.4195PMC PMC6126939

Open this paper in CoChat — free account

Abstract

The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding tumors can be enhanced by administering the cells in combination with immune checkpoint blockade inhibitors. Alternatively, the CAR construct has been engineered to coexpress factors that boost CAR-T cell function in the tumor microenvironment. We modified CAR-T cells to secrete PD-1-blocking single-chain variable fragments (scFv). These scFv-secreting CAR-T cells acted in both a paracrine and autocrine manner to improve the anti-tumor activity of CAR-T cells and bystander tumor-specific T cells in clinically relevant syngeneic and xenogeneic mouse models of PD-L1+ hematologic and solid tumors. The efficacy was similar to or better than that achieved by combination therapy with CAR-T cells and a checkpoint inhibitor. This approach may improve safety, as the secreted scFvs remained localized to the tumor, protecting CAR-T cells from PD-1 inhibition, which could potentially avoid toxicities associated with systemic checkpoint inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.4195

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
In-gel digestion for mass spectrometric characterization of proteins and proteomes
Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,947
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citation
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 101–200 of 831

Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 100
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00262 · Cited by 98
Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P. O., Xu-Monette, Z. Y., Li, L., Zhang, M., Young, K. H., Ma, X., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-00257-z · Cited by 95
Self-citation
Engineering better chimeric antigen receptor T cells
Zhang, H., Zhao, P., & Huang, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00190-2 · Cited by 93
Determinants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 96
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092158 · Cited by 97
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Kong, Y., Li, J., Zhao, X., Wu, Y., & Chen, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1519671 · Cited by 96
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
Lee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 89
Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
Cheever, A., Townsend, M. H., & O'Neill, K. L. (2022) · Cells · doi:10.3390/cells11223626 · Cited by 94
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
Roselli, E., Faramand, R. G., & Davila, M. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142030 · Cited by 90
Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells
Liu, L., Chen, J., Bae, J., Li, H., Sun, Z., Moore, C., Hsu, E. J., Han, C., Qiao, J., & Fu, Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00800-2 · Cited by 87
The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.
Zhao, W., Jia, L., Zhang, M., Huang, X., Qian, P., Tang, Q., Zhu, J., & Feng, Z. (2019) · PubMed Central · Cited by 85
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 88
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
Chen, C., Gu, Y., Zhang, F., Zhang, Z.-C., Zhang, Y., He, Y.-D., Wang, L., Zhou, N., Tang, F., Liu, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1901434 · Cited by 88
Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects
Poorebrahim, M., Sadeghi, S., Fakhr, E., Abazari, M. F., Poortahmasebi, V., Kheirollahi, A., Askari, H., Rajabzadeh, A., Rastegarpanah, M., Linē, A., et al. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1633512 · Cited by 83
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Watanabe, N., McKenna, M. K., Shaw, A. R., & Suzuki, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.023 · Cited by 84
Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
Miao, L., Zhang, Z., Ren, Z., Tang, F., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687822 · Cited by 83
Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
Gao, Q., Dong, X., Xu, Q., Zhu, L., Wang, F., Hou, Y., & Chao, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2257 · Cited by 85
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Andreu-Saumell, I., Rodríguez-García, A., Mühlgrabner, V., Giménez-Alejandre, M., Marzal, B., Castellsagué, J., Brasó‐Maristany, F., Calderón, H., Angelats, L., Colell, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47799-z · Cited by 87
Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease
Chang, Y., Zhao, X., & Huang, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03041 · Cited by 81
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
Wudhikarn, K., Flynn, J. R., Rivière, I., Gönen, M., Wang, X., Sénéchal, B., Curran, K. J., Roshal, M., Maslak, P. G., Geyer, M. B., et al. (2021) · Blood · doi:10.1182/blood.2020009515 · Cited by 80
Self-citation
Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
Zhang, C., Hu, Y., Xiao, W., & Tian, Z. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00732-6 · Cited by 80
Cell–drug conjugates
Wang, Y., Shi, J., Xin, M., Kahkoska, A. R., Wang, J., & Gu, Z. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01230-6 · Cited by 82
CAR‐T Cells: Future Perspectives
Charrot, S., & Hallam, S. L. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000188 · Cited by 80
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Long, K. B., Young, R. M., Boesteanu, A. C., Suhoski, M. M., Melenhorst, J. J., Lacey, S. F., Degaramo, D. A., Levine, B. L., & Fraietta, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02740 · Cited by 80
Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models
Volpe, A., Lang, C., Lim, L., Man, F., Kurtys, E., Ashmore‐Harris, C., Johnson, P., Skourti, E., de Rosales, R. T. M., & Fruhwirth, G. O. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.028 · Cited by 82
CAR‐T cell therapy for lung cancer: Potential and perspective
Chen, L., Chen, F., Li, J., Pu, Y., Yang, C., Wang, Y., Lei, Y., & Huang, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14375 · Cited by 78
Nanomedicine-based cancer immunotherapy: recent trends and future perspectives
Lakshmanan, V., Jindal, S., Packirisamy, G., Ojha, S. K., Lian, S., Kaushik, A. K., Alzarooni, A. I. M. A., Metwally, Y. H. H., Thyagarajan, S. P., Jung, Y. D., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00299-4 · Cited by 78
Engineering CAR-T cells to activate small-molecule drugs in situ
Gardner, T. J., Lee, J. P., Bourne, C. M., Wijewarnasuriya, D., Kinarivala, N., Kurtz, K. G., Corless, B. C., Dacek, M. M., Chang, A. Y., Mo, G., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00932-1 · Cited by 76
Self-citation
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Andrea, A. E., Chiron, A., Mallah, S., Bessoles, S., Sarrabayrouse, G., & Hacein‐Bey‐Abina, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830292 · Cited by 75
Deep Downregulation of PD‐L1 by Caged Peptide‐Conjugated AIEgen/miR‐140 Nanoparticles for Enhanced Immunotherapy
Dai, J., Hu, J., Dong, X., Chen, B., Dong, X., Liu, R., Xia, F., & Lou, X. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202117798 · Cited by 75
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 76
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 78
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Li, X., Daniyan, A. F., Lopez, A. V., Purdon, T. J., & Brentjens, R. J. (2020) · Leukemia · doi:10.1038/s41375-020-0874-1 · Cited by 73
Self-citation
Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy
Dai, Z., Wang, Q., Tang, J., Wu, M., Li, H., Yang, Y., Xu, Z. C., & Yu, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121261 · Cited by 72
Designing drug delivery systems for cell therapy
Wang, L., Gao, Y., Feng, Z., Mooney, D. J., & Mitragotri, S. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00214-0 · Cited by 76
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
Lamplugh, Z. L., Wellhausen, N., June, C. H., & Fan, Y. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01229-3 · Cited by 76
T Cell Exhaustion and CAR‐T Immunotherapy in Hematological Malignancies
Tang, L., Zhang, Y., Hu, Y., & Mei, H. (2021) · BioMed Research International · doi:10.1155/2021/6616391 · Cited by 72
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 72
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 71
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
Song, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 68
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung
Zhu, T., Xiao, Y., Chen, Z., Ding, H., Chen, S., Jiang, G., & Huang, X. (2025) · Nature Communications · doi:10.1038/s41467-024-55751-4 · Cited by 68
Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
Liu, H., Guo, L., Zhang, J., Zhou, Y., Zhou, J., Yao, J., Wu, H., Yao, S., Chen, B., Chai, Y., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1596513 · Cited by 68
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Springuel, L., Lonez, C., Alexandre, B., Cutsem, E. V., Machiels, J., den Eynde, M. V., Prenen, H., Hendlisz, A., Shaza, L., Carrasco, J., et al. (2019) · BioDrugs · doi:10.1007/s40259-019-00368-z · Cited by 69
Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies
Chyuan, I., Chu, C., & Hsu, P. (2021) · Cancers · doi:10.3390/cancers13061188 · Cited by 68
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 68
Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling
Zhou, M., Chen, M., Shi, B., Di, S., Sun, R., Jiang, H., & Li, Z. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.021 · Cited by 67
Self-citation
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy
Wang, Y., Zhou, S., Wang, Y., Lu, Z.-D., Zhang, Y., Xu, C., & Wang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-37656-w · Cited by 67
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 68
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 67
Programmable synthetic receptors: the next-generation of cell and gene therapies
Teng, F., Cui, T., Zhou, L., Gao, Q., Zhou, Q., & Li, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01680-5 · Cited by 70
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 68
Self-citation
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
Jung, M., Yang, Y., McCloskey, J. E., Zaman, M., Vedvyas, Y., Zhang, X., Stefanova, D. I., Gray, K. D., Min, I. M., Zarnegar, R., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.009 · Cited by 64
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
Jin, C., Xia, J., Rafiq, S., Huang, X., Hu, Z., Zhou, X., Brentjens, R. J., & Yang, Y. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.013 · Cited by 65
Self-citation
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
Roex, G., Feys, T., Beguin, Y. P., Kerre, T. C. C., Poiré, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020194 · Cited by 65
Immune-Based Therapies in Acute Leukemia
Witkowski, M. T., Lasry, A., Carroll, W. L., & Aifantis, I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.009 · Cited by 65
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
Sang, W., Wang, X., Geng, H., Li, T., Li, D., Zhang, B., Zhou, Y., Song, X., Sun, C., Yan, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858021 · Cited by 62
Self-citation
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhou, Z., Wang, J., Wang, J., Yang, S., Wang, R., Zhang, G., Li, Z., Shi, R., Wang, Z., & Lu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02047-2 · Cited by 66
Self-citation
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
Chen, H., Yang, Y., Deng, Y., Wei, F., Zhao, Q., Liu, Y., Liu, Z., Yu, B., & Huang, Z. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003737 · Cited by 64
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2220 · Cited by 63
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 62
The antigen‐binding moiety in the driver's seat of CARs
Hanssens, H., Meeus, F., Veirman, K. D., Breckpot, K., & Devoogdt, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21818 · Cited by 63
Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
Li, F., Zhao, S., Cheng, W., Hu, Y., Xu, T., Xin, X., Zhu, T., Shang, L., Ke, S., Zhou, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958082 · Cited by 62
Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Patel, S., Burga, R. A., Powell, A. B., Chorvinsky, E. A., Hoq, N., McCormack, S., Pelt, S. N. V., Hanley, P. J., & Cruz, C. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00196 · Cited by 60
Engineering chimeric antigen receptor T cells for solid tumour therapy
Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 61
CAR T cells and checkpoint inhibition for the treatment of glioblastoma
Shen, S. H., Woroniecka, K. I., Barbour, A. B., Fecci, P. E., Sanchez-Perez, L. A., & Sampson, J. H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1727436 · Cited by 62
CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
Li, H., Yang, C., Cheng, H., Huang, S., & Zheng, Y. (2021) · Journal of Cancer · doi:10.7150/jca.50509 · Cited by 59
Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors
Fu, R., Li, H., Li, R., McGrath, K. V., Dotti, G., & Gu, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009489 · Cited by 58
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials
Yadav, D., Kwak, M., Chauhan, P., Puranik, N., Lee, P. C.-W., & Jin, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.016 · Cited by 58
Customized Multifunctional Peptide Hydrogel Scaffolds for CAR-T-Cell Rapid Proliferation and Solid Tumor Immunotherapy
Jie, J., Mao, D., Cao, J., Feng, P.-F., & Yang, P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c10727 · Cited by 59
The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors
Wang, L., Zhang, L., Dunmall, L. C., Wang, Y. Y., Fan, Z., Cheng, Z., & Wang, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216871 · Cited by 59
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 60
Glycosylation of Immune Receptors in Cancer
Sun, R., Kim, A. M. J., & Lim, S. (2021) · Cells · doi:10.3390/cells10051100 · Cited by 58
Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy
McGrath, K. V., & Dotti, G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.278 · Cited by 57
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
Ventin, M., Cattaneo, G., Maggs, L., Arya, S., Wang, X., & Ferrone, C. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4504 · Cited by 64
T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies
Blanco, B., Compte, M., Lykkemark, S., Sanz, L., & Álvarez‐Vallina, L. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.008 · Cited by 59
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 60
PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Peng, Z., Li, M., Li, H., & Gao, Q. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103666 · Cited by 57
Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions
Hosea, R., Hillary, S., Wu, S., & Kasim, V. (2023) · Cancers · doi:10.3390/cancers15133506 · Cited by 57
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
Holthof, L. C., van der Schans, J. J., Katsarou, A., Poels, R., Gelderloos, A. T., Drent, E., Veen, S. E. V. H.-V., Li, F., Zweegman, S., van de Donk, N. W. C. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2188 · Cited by 55
CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer
Włodarczyk, M., & Pyrzyńska, B. (2022) · Cancers · doi:10.3390/cancers15010117 · Cited by 54
CAR-T cell therapy for lung cancer: a promising but challenging future
Zhong, S., Cui, Y., Liu, Q., & Chen, S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.118 · Cited by 53
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Gray, K. D., McCloskey, J. E., Vedvyas, Y., Kalloo, O. R., Eshaky, S. E., Yang, Y., Shevlin, E., Zaman, M., Ullmann, T. M., Liang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1523 · Cited by 53
Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells
Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 53
Aptamer‑T Cell Targeted Therapy for Tumor Treatment Using Sugar Metabolism and Click Chemistry
Liu, C.-G., Wang, Y., Liu, P., Yao, Q., Zhou, Y., Li, C., Zhao, Q., Liu, G., & Zhang, X. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00164 · Cited by 53
Self-citation
Engineering CAR T Cells to Target the HIV Reservoir
Mu, W., Carrillo, M. A., & Kitchen, S. G. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00410 · Cited by 55
Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model
Song, Y., Liu, Q., Zuo, T., Wei, G., & Jiao, S. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104112 · Cited by 52
A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
Liu, X., Zhang, Y., Li, K., Liu, Y., Xu, J., Ma, J., An, L., Wang, H., & Chu, X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101085 · Cited by 52
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy
Lanitis, E., Coukos, G., & Irving, M. B. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.009 · Cited by 52
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Zhang, X., Wu, Y., Xu, T., & Cui, M. (2023) · Biomolecules · doi:10.3390/biom13030465 · Cited by 53
A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice
Jin, G., Liu, Y., Wang, L., He, Z., Zhao, X., Ma, Y., Jia, Y., Li, Z., Yin, N., & Peng, M. (2024) · Nature Immunology · doi:10.1038/s41590-024-01834-9 · Cited by 51
Self-citation
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors
Zhu, C., Liu, C., Wu, Q., Sheng, T., Zhou, R., Ren, E., Zhang, R., Zhao, Z., Shi, J., Shen, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02028-3 · Cited by 51
Self-citation
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 59
Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51
Nano/genetically engineered cells for immunotherapy
Shen, J., Zhou, Y., & Yin, L. (2024) · BMEMat · doi:10.1002/bmm2.12112 · Cited by 50
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery
Murad, J. P., Christian, L., Rosa, R. C. A., Ren, Y., Buckley, A. J., Lee, E. H. J., Lopez, L. S., Park, A. K., Yang, J., Yamaguchi, Y., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01509-2 · Cited by 52
B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models
Huang, B., Luo, L., Wang, J., He, B., Feng, R., Xian, N., Zhang, Q., Chen, L., & Huang, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1684127 · Cited by 50

Authors: Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., Yan, S., Xiang, J., Ma, X., Seshan, V. E., Hendrickson, R. C., Liu, C., & Brentjens, R. J.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Cornell University (US)
Weill Cornell Medicine (US)
Eureka Therapeutics (United States) (US)
Corresponding author: Brentjens, Renier J
ORCID: Rafiq, Sarwish
Yeku, Oladapo O
Purdon, Terence J
van Leeuwen, Dayenne G
Drakes, Dylan J
Song, Mei
Miele, Matthew M
Li, Zhuoning
Yan, Su
Xiang, Jingyi
Ma, Xiaojing
Seshan, Venkatraman E
Hendrickson, Ronald C
Brentjens, Renier J
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2018-08-13
Volume: 36
Issue: 9
Pages: 847-856
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4195
PMC: PMC6126939
OpenAlex: W2886131798
Cited by: 833
References: 46
Citations by year: 2026: 78 · 2025: 94 · 2024: 91 · 2023: 114 · 2022: 123 · 2021: 121 · 2020: 122 · 2019: 72 · 2018: 14
FWCI: 31.01
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (1s10od010598-01)
National Cancer Institute (P01CA190174, P50CA192937, P30CA008748)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: chimeric antigen receptor T cells, anti-PD-1 therapy, scFv, chimeric antigen receptor, immune checkpoint blockade, PD-L1, paracrine signaling, autocrine signaling, bystander T cells, tumor microenvironment, hematologic malignancies, solid tumors, CAR T cell safety
MeSH terms: Receptors, Chimeric Antigen, Animals, Humans, T-Lymphocytes, Xenograft Model Antitumor Assays, Mice, Single-Chain Antibodies, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks